- Home
- AVDL
as 12-26-2024 4:00pm EST
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.
| Founded: | 2015 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN |
| Market Cap: | 993.5M | IPO Year: | 1996 |
| Target Price: | $24.00 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.41 - $19.09 | Next Earning Date: | 11-12-2024 |
| Revenue: | $138,160,000 | Revenue Growth: | 1523.50% |
| Revenue Growth (this year): | 523.86% | Revenue Growth (next year): | 70.46% |
Stock Insider Trading Activity of Avadel Pharmaceuticals plc (AVDL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MCHUGH THOMAS S | AVDL | Chief Financial Officer | Dec 11 '24 | Buy | $10.49 | 5,000 | $52,432.50 | 85,500 | |
| Glass Geoffrey Michael | AVDL | Director | Dec 10 '24 | Buy | $9.85 | 20,279 | $199,640.95 | 69,075 | |
| Divis Gregory J | AVDL | Chief Executive Officer | Dec 6 '24 | Buy | $9.90 | 10,000 | $99,706.89 | 9,598 | |
| Palczuk Linda | AVDL | Director | Dec 6 '24 | Buy | $10.19 | 3,000 | $30,567.60 | 66,400 |
Latest Avadel Pharmaceuticals plc News
AVDL Breaking Stock News: Dive into AVDL Ticker-Specific Updates for Smart Investing
Simply Wall St.
15 days ago
Independent Non-Executive Chairman of the Board of Avadel Pharmaceuticals Picks Up 16% More Stock
GlobeNewswire
16 days ago
Results from Social Listening Analysis and Survey of People with Narcolepsy Uncover Real-Life Challenges with Twice-Nightly Oxybate Therapy
MT Newswires
a month ago
UBS Adjusts Price Target on Avadel Pharmaceuticals to $22 From $25, Maintains Buy Rating
Simply Wall St.
a month ago
Avadel Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
GlobeNewswire
a month ago
Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference
GuruFocus.com
a month ago
Avadel Pharmaceuticals PLC (AVDL) Q3 2024 Earnings Call Highlights: Strong Patient Growth and ...
MT Newswires
a month ago
Avadel Pharmaceuticals' Q3 Loss Narrows, Revenue Rises
Associated Press Finance
a month ago
Avadel: Q3 Earnings Snapshot
Compare AVDL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AVDL Avadel Pharmaceuticals plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.